Comments from readers on the Summer 2014 issue of CURE.
Easier Said Than Done
I read Dr. Lichtenfeld’s “House Call” column with great interest and heartily agree with his statement “Survivors must be their own best advocates.” As an eight-year appendiceal cancer survivor, I suffer the long-term results of extensive radiation to my pelvic area. While I have managed my symptoms through the years, I have suffered greatly and eliminated foods from my diet through painful trial and error. I have had plenty of support from my oncologist and gastroenterologist, but neither they nor the myriad survivors I read online have information that is specific to my needs. Sometimes being our own advocates isn’t easy. There’s just nowhere to turn.
Portia Little, Shawnee, Okla.
The Rest of the Story
In response to “New Guidelines Recommend Genetic Testing for Lynch Syndrome,” you owe your readers an additional piece of information: The cost is prohibitive to most patients. My husband has a strong family history of colorectal cancer and we suspected a possible Lynch syndrome connection. We were told by our genetic counselor that the test for Lynch syndrome was $4,000. There are thousands of families just like my husband’s who would benefit from preventive measures if this blood test could be reasonably obtained.
Kathryn E. Koshan, PharmD, New Smyrna Beach, Fla.
Relief from Neuropathy
I was compelled to write after reading the article on coping with peripheral neuropathy (“Lessons Learned”). In June 2012, I asked the physician assistant in my neurologist’s office about supplements. She mentioned alphalipoic acid. So, I picked some up, and within a couple of days I was not waking up through the night with the electrical feelings shooting through my feet and up my legs. Are they completely gone? No, but the difference is nothing short of a godsend.
Karen Armstrong, Rochester, N.Y.
Editor-at-Large Kathy LaTour responds: The studies on alpha-lipoic acid have mixed results, so I chose not to include it. Any supplements taken during treatment should be reviewed by a physician.
Access the Archive
After receiving several issues of CURE, there seems to be a strong focus on breast cancer and lymphomas but almost nothing on bladder cancer—reflecting the same preponderance in the popular media. Considering the prevalence of bladder cancer, I would think you could broaden that focus.
Marilyn Traiger, Hartford, Conn.
Managing Editor Jon Garinn responds: CURE recently focused on advances in treating bladder cancer (“Advances in Bladder Cancer Treatment Around the Corner,” Spring 2012). Access the full article in the magazine archive at curetoday.com.